A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B

The New England Journal of Medicine
Ting-Tsung ChangBEHoLD AI463022 Study Group

Abstract

Entecavir is a potent and selective guanosine analogue with significant activity against hepatitis B virus (HBV). In this phase 3, double-blind trial, we randomly assigned 715 patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B who had not previously received a nucleoside analogue to receive either 0.5 mg of entecavir or 100 mg of lamivudine once daily for a minimum of 52 weeks. The primary efficacy end point was histologic improvement (a decrease by at least two points in the Knodell necroinflammatory score, without worsening of fibrosis) at week 48. Secondary end points included a reduction in the serum HBV DNA level, HBeAg loss and seroconversion, and normalization of the alanine aminotransferase level. Histologic improvement after 48 weeks occurred in 226 of 314 patients in the entecavir group (72 percent) and 195 of 314 patients in the lamivudine group (62 percent, P=0.009). More patients in the entecavir group than in the lamivudine group had undetectable serum HBV DNA levels according to a polymerase-chain-reaction assay (67 percent vs. 36 percent, P<0.001) and normalization of alanine aminotransferase levels (68 percent vs. 60 percent, P=0.02). The mean reduction in serum HBV DNA from baseline to we...Continue Reading

References

Sep 1, 1981·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·R G KnodellJ Wollman
Aug 30, 1996·Statistics in Medicine·C W Dunnett, M Gent
Jul 1, 1997·Antimicrobial Agents and Chemotherapy·S F InnaimoR J Colonno
Dec 11, 1997·The New England Journal of Medicine·W M Lee
Jul 9, 1998·The New England Journal of Medicine·C L LaiD F Gray
Jul 27, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Y F LiawC M Chu
Oct 21, 1999·The New England Journal of Medicine·J L DienstagN A Brown
Sep 26, 2000·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·D T LauJ H Hoofnagle
Jun 8, 2001·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·N W LeungUNKNOWN Asia Hepatitis Lamivudine Study Group
Jun 9, 2001·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·D Mutimer
Jan 4, 2003·Gastroenterology·Jules L DienstagEugene R Schiff
Feb 27, 2003·Journal of Gastroenterology and Hepatology·Yun-Fan LiawUNKNOWN Asian-Pacific Consensus Working Parties on Hepatitis B
Feb 28, 2003·The New England Journal of Medicine·Patrick MarcellinUNKNOWN Adefovir Dipivoxil 437 Study Group
May 3, 2003·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Anna AyresStephen Locarnini
Oct 8, 2004·The New England Journal of Medicine·Yun-Fan LiawUNKNOWN Cirrhosis Asian Lamivudine Multicentre Study Group
Oct 16, 2004·Journal of Gastroenterology and Hepatology·Ting-Tsung ChangNancy Wy Leung
Nov 27, 2004·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Morris Sherman, Andrew Klein
Feb 17, 2005·Journal of the National Cancer Institute·Ming-Whei YuChien-Jen Chen
Jul 1, 2005·The New England Journal of Medicine·Stephanos J HadziyannisUNKNOWN Adefovir Dipivoxil 438 Study Group
Jul 1, 2005·The New England Journal of Medicine·George K K LauUNKNOWN Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group
Jan 5, 2006·JAMA : the Journal of the American Medical Association·Chien-Jen ChenUNKNOWN REVEAL-HBV Study Group

❮ Previous
Next ❯

Citations

May 3, 2011·Langenbeck's Archives of Surgery·Arianeb MehrabiTom M Ganten
May 29, 2007·Journal of Gastroenterology·Hiroshi Yotsuyanagi, Kazuhiko Koike
Jul 21, 2012·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Mehlika ToyCihan Yurdaydin
Feb 3, 2009·Journal of Urban Health : Bulletin of the New York Academy of Medicine·Shaili Gupta, Frederick L Altice
Jun 19, 2013·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Ming-Fa ChenJun Wu
Jan 5, 2011·Journal of General Internal Medicine·Tatyana A ShamliyanTimothy J Wilt
Mar 6, 2007·Current Gastroenterology Reports·Robert G Gish
Jan 27, 2009·Current Gastroenterology Reports·John D Scott, Brian McMahon
May 31, 2008·Current HIV/AIDS Reports·Vincent SorianoPablo Barreiro
Aug 25, 2009·Current Infectious Disease Reports·Melissa Osborn
Aug 12, 2009·Hepatology International·Yock Young DanSeng Gee Lim
Jun 1, 2008·Hepatology International·Shiv Kumar Sarin, Manoj Kumar
Aug 12, 2009·Hepatology International·Yun-Fan LiawUNKNOWN Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver
Aug 12, 2009·Hepatology International·Ching-Lung Lai, Man-Fung Yuen
Mar 27, 2013·Paediatric Drugs·Mona Abdel-Hady, Deirdre Kelly
Oct 6, 2010·Cellular & Molecular Immunology·Yanfang JiangJunqi Niu
Oct 25, 2011·Eye·M K M MuqitN Patton
Jun 3, 2008·Therapeutics and Clinical Risk Management·Evangelini DimouStephanos J Hadziyannis
Aug 3, 2006·Nature Clinical Practice. Gastroenterology & Hepatology·Smruti R MohantyVijay Khiani
Apr 26, 2007·Nature Reviews. Drug Discovery·Jules DienstagPeter Kirkpatrick
Mar 23, 2011·Nature Reviews. Gastroenterology & Hepatology·Hellan Kwon, Anna S Lok
Jul 21, 2006·The New England Journal of Medicine·Ting-Tsung Chang, Ching-Lung Lai
Mar 10, 2006·The New England Journal of Medicine·Jay H Hoofnagle
Mar 10, 2006·The New England Journal of Medicine·Ching-Lung LaiUNKNOWN BEHoLD AI463027 Study Group
Dec 21, 2007·The New England Journal of Medicine·Ching-Lung LaiUNKNOWN Globe Study Group
Dec 5, 2008·The New England Journal of Medicine·Patrick MarcellinFranck Rousseau
Oct 4, 2008·The New England Journal of Medicine·Jules L Dienstag
Oct 6, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Wang-Huei ShengShan-Chwen Chang
Oct 9, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·I-Chin WuTing-Tsung Chang
Oct 9, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Mindie H Nguyen, Emmet B Keeffe
Oct 20, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Debika Bhattacharya, Chloe L Thio
Aug 13, 2009·The Journal of Antimicrobial Chemotherapy·C Y William TongTerry Wong
Nov 11, 2009·The Journal of Antimicrobial Chemotherapy·K LacombeP M Girard
Oct 4, 2011·The Journal of Antimicrobial Chemotherapy·James FungMan-Fung Yuen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Related Papers

The New England Journal of Medicine
Ching-Lung LaiBEHoLD AI463027 Study Group
The New England Journal of Medicine
George K K LauPeginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group
The New England Journal of Medicine
Ching-Lung LaiGlobe Study Group
© 2021 Meta ULC. All rights reserved